These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 10613780)
41. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. Campana S; Taccetti G; Ravenni N; Masi I; Audino S; Sisi B; Repetto T; Döring G; de Martino M J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902 [TBL] [Abstract][Full Text] [Related]
42. Comparison of culture and PCR for detection of Burkholderia cepacia in sputum samples of patients with cystic fibrosis. Whitby PW; Dick HL; Campbell PW; Tullis DE; Matlow A; Stull TL J Clin Microbiol; 1998 Jun; 36(6):1642-5. PubMed ID: 9620393 [TBL] [Abstract][Full Text] [Related]
43. Direct detection of N-acylhomoserine lactones in cystic fibrosis sputum. Middleton B; Rodgers HC; Cámara M; Knox AJ; Williams P; Hardman A FEMS Microbiol Lett; 2002 Jan; 207(1):1-7. PubMed ID: 11886742 [TBL] [Abstract][Full Text] [Related]
44. Cloaking antibodies are prevalent in Pham A; Tan KKY; Ledger EL; Smith DJ; Reid DW; Burr L; Chambers DC; Wells TJ Front Cell Infect Microbiol; 2024; 14():1426773. PubMed ID: 39193503 [TBL] [Abstract][Full Text] [Related]
45. A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia. Ledson MJ; Gallagher MJ; Robinson M; Cowperthwaite C; Williets T; Hart CA; Walshaw MJ J Aerosol Med; 2002; 15(1):51-7. PubMed ID: 12006145 [TBL] [Abstract][Full Text] [Related]
46. Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia. Jacques I; Derelle J; Weber M; Vidailhet M Eur J Pediatr; 1998 May; 157(5):427-31. PubMed ID: 9625343 [TBL] [Abstract][Full Text] [Related]
47. Suppurative mediastinitis secondary to Burkholderia cepacia in a patient with cystic fibrosis. George RB; Cartier Y; Casson AG; Hernandez P Can Respir J; 2006; 13(4):215-8. PubMed ID: 16779467 [TBL] [Abstract][Full Text] [Related]
48. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Hughes JE; Stewart J; Barclay GR; Govan JR Infect Immun; 1997 Oct; 65(10):4281-7. PubMed ID: 9317038 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of contamination of the dentist and dental surgery environment with Burkholderia (Pseudomonas) cepacia during treatment of children with cystic fibrosis. Pankhurst CL; Harrison VE; Philpott-Howard J Int J Paediatr Dent; 1995 Dec; 5(4):243-7. PubMed ID: 8957838 [TBL] [Abstract][Full Text] [Related]
50. Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Coenye T; LiPuma JJ; Henry D; Hoste B; Vandemeulebroecke K; Gillis M; Speert DP; Vandamme P Int J Syst Evol Microbiol; 2001 Mar; 51(Pt 2):271-9. PubMed ID: 11321071 [TBL] [Abstract][Full Text] [Related]
51. Fatal outcome of lung transplantation in cystic fibrosis patients due to small-colony variants of the Burkholderia cepacia complex. Häussler S; Lehmann C; Breselge C; Rohde M; Classen M; Tümmler B; Vandamme P; Steinmetz I Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):249-53. PubMed ID: 12687415 [TBL] [Abstract][Full Text] [Related]
52. Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis. McCloskey M; McCaughan J; Redmond AO; Elborn JS Ir J Med Sci; 2001; 170(1):28-31. PubMed ID: 11440408 [TBL] [Abstract][Full Text] [Related]
53. Defining potential targets for immunotherapy in Burkholderia cepacia infection. Burnie JP; al-Wardi EJ; Williamson P; Matthews RC; Webb K; David T FEMS Immunol Med Microbiol; 1995 Jan; 10(2):157-64. PubMed ID: 7536517 [TBL] [Abstract][Full Text] [Related]
54. Identification of Pseudomonas aeruginosa, Burkholderia cepacia complex, and Stenotrophomonas maltophilia in respiratory samples from cystic fibrosis patients using multiplex PCR. da Silva Filho LV; Tateno AF; Velloso Lde F; Levi JE; Fernandes S; Bento CN; Rodrigues JC; Ramos SR Pediatr Pulmonol; 2004 Jun; 37(6):537-47. PubMed ID: 15114555 [TBL] [Abstract][Full Text] [Related]
55. Serum sensitivity of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis. Butler SL; Nelson JW; Poxton IR; Govan JR FEMS Immunol Med Microbiol; 1994 May; 8(4):285-92. PubMed ID: 7520313 [TBL] [Abstract][Full Text] [Related]
56. Burkholderia Sepsis in Children as a Hospital-Acquired Infection. Kim KY; Yong D; Lee K; Kim HS; Kim DS Yonsei Med J; 2016 Jan; 57(1):97-102. PubMed ID: 26632388 [TBL] [Abstract][Full Text] [Related]
57. Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. Kiska DL; Kerr A; Jones MC; Caracciolo JA; Eskridge B; Jordan M; Miller S; Hughes D; King N; Gilligan PH J Clin Microbiol; 1996 Apr; 34(4):886-91. PubMed ID: 8815102 [TBL] [Abstract][Full Text] [Related]
58. Susceptibility of Burkholderia cepacia and other pathogens of importance in cystic fibrosis to u.v. light. Cairns G; Kerr KG; Beggs CB; Sleigh PA; Mooney L; Keig P; Donnelly JK Lett Appl Microbiol; 2001 Mar; 32(3):135-8. PubMed ID: 11264740 [TBL] [Abstract][Full Text] [Related]
59. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. Courtney JM; Dunbar KE; McDowell A; Moore JE; Warke TJ; Stevenson M; Elborn JS J Cyst Fibros; 2004 Jun; 3(2):93-8. PubMed ID: 15463892 [TBL] [Abstract][Full Text] [Related]
60. [Burkholderia cepacia: a new pathogen causing nosocomial infections]. Lipowski D; Rzadkiewicz E; Czekalska-Lachowicz E Przegl Epidemiol; 2008; 62(1):7-17. PubMed ID: 18536220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]